ChemoCentryx, Inc.:製薬企業の製品開発パイプライン分析2014

◆英語タイトル:ChemoCentryx, Inc. - Product Pipeline Review - 2014
◆商品コード:GMDHC04970CDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年6月25日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

ChemoCentryx, Inc. – Product Pipeline Review – 2014

Summary

Global Markets Direct’s, ‘ChemoCentryx, Inc. – Product Pipeline Review – 2014’, provides an overview of the ChemoCentryx, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ChemoCentryx, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ChemoCentryx, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ChemoCentryx, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ChemoCentryx, Inc.’s pipeline products

Reasons to buy

- Evaluate ChemoCentryx, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ChemoCentryx, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ChemoCentryx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ChemoCentryx, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ChemoCentryx, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ChemoCentryx, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
ChemoCentryx, Inc. Snapshot 6
ChemoCentryx, Inc. Overview 6
Key Information 6
Key Facts 6
ChemoCentryx, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
ChemoCentryx, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
ChemoCentryx, Inc. – Pipeline Products Glance 12
ChemoCentryx, Inc. – Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
ChemoCentryx, Inc. – Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
ChemoCentryx, Inc. – Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
ChemoCentryx, Inc. – Drug Profiles 17
CCX-140 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CCX-168 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CCX-354 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
vercirnon sodium 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CCX-507 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CCX-872 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CCX-1378 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CCX-1641 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CCX-6239 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CCX-650 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CCX-771 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule Antagonist Of CCR6 for Autoimmune and Inflammatory Disorders 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule Antagonist Of CXCR6 for Autoimmune and Liver Diseases 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule Antagonists Of CCR1 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Antagonize CCR and CXCR for Oncology and Autoimmune Disease 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCR2-3G 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CCR9-3G 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CCX-956 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ChemoCentryx, Inc. – Pipeline Analysis 37
ChemoCentryx, Inc. – Pipeline Products by Target 37
ChemoCentryx, Inc. – Pipeline Products by Route of Administration 39
ChemoCentryx, Inc. – Pipeline Products by Molecule Type 40
ChemoCentryx, Inc. – Pipeline Products by Mechanism of Action 41
ChemoCentryx, Inc. – Recent Pipeline Updates 43
ChemoCentryx, Inc. – Dormant Projects 51
ChemoCentryx, Inc. – Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
CCX-832 52
vercirnon sodium 52
ChemoCentryx, Inc. – Locations And Subsidiaries 53
Head Office 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
ChemoCentryx, Inc., Key Information 6
ChemoCentryx, Inc., Key Facts 6
ChemoCentryx, Inc. - Pipeline by Indication, 2014 8
ChemoCentryx, Inc. - Pipeline by Stage of Development, 2014 10
ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2014 11
ChemoCentryx, Inc. - Phase II, 2014 12
ChemoCentryx, Inc. - Phase I, 2014 13
ChemoCentryx, Inc. - Preclinical, 2014 14
ChemoCentryx, Inc. - Discovery, 2014 15
ChemoCentryx, Inc. - Unknown, 2014 16
ChemoCentryx, Inc. - Pipeline by Target, 2014 38
ChemoCentryx, Inc. - Pipeline by Route of Administration, 2014 39
ChemoCentryx, Inc. - Pipeline by Molecule Type, 2014 40
ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2014 42
ChemoCentryx, Inc. - Recent Pipeline Updates, 2014 43
ChemoCentryx, Inc. - Dormant Developmental Projects,2014 51
ChemoCentryx, Inc. - Discontinued Pipeline Products, 2014 52

List of Figures
ChemoCentryx, Inc. - Pipeline by Top 10 Indication, 2014 8
ChemoCentryx, Inc. - Pipeline by Stage of Development, 2014 10
ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2014 11
ChemoCentryx, Inc. - Pipeline by Top 10 Target, 2014 37
ChemoCentryx, Inc. - Pipeline by Top 10 Route of Administration, 2014 39
ChemoCentryx, Inc. - Pipeline by Top 10 Molecule Type, 2014 40
ChemoCentryx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 41

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ChemoCentryx, Inc.:製薬企業の製品開発パイプライン分析2014]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆